DARA Key Stats
|Revenue (Quarterly YoY Growth)|
|EPS Diluted (TTM)||-0.4099|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-9.482M|
|Gross Profit Margin (Quarterly)||10.68%|
|Profit Margin (Quarterly)||-1825%|
|Dividend Yield (TTM)||0.00%|
|Payout Ratio (TTM) Pro||Go Pro|
- Nasdaq stocks posting largest volume increases Dec 6
- DARA BioSciences Completes Breast Cancer CAPTURE Registry noodls Dec 3
- DARA Bio (DARA) Files 5M Common Shelf for Shareholders Street Insider Nov 27
- DARA: Building An Oncology And Supportive Care Specialty Pharma Nov 15
- DARA BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, F Nov 14
- DARA Reports Third Quarter 2013 Financial Results and Highlights Commercial Momentum on Synergistic Oncology Supportive Care Product Portfolio noodls Nov 14
- Dara Biosciences, Inc. (DARA) Posts Q3 Loss of 10c/Share Street Insider Nov 14
- DARA BIOSCIENCES, INC. Files SEC form 10-Q, Quarterly Report Nov 13
- NASDAQ Grants DARA BioSciences 180-Day Extension to Regain Compliance With Bid Price Requirement noodls Nov 12
- DARA BIOSCIENCES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stan Nov 12
DARA Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). DARA Biosciences is down 38.62% over the last year vs S&P 500 Total Return up 29.71%, AEterna Zentaris down 49.31%, and Alcobra up N/A.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for DARA
Pro Strategies Featuring DARA
Did DARA Biosciences make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
DARA Biosciences, Inc., is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products.